AAVANTGARDE
LIVE

Serial Number

98346994

Owner

AAVantgarde Bio Srl

Attorney

Scott J. Major

Filing Date

Jan 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AAVANTGARDE Trademark

Serial Number: 98346994 • Registration: 8140404

AAVANTGARDE is a trademark filed by AAVantgarde Bio Srl on January 8, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

AAVantgarde Bio Srl (2 trademarks)

8 Via Vincenzo Gioberti
Milan 20123 , IT

Entity Type: 99

Trademark Details

Filing Date

January 8, 2024

Registration Date

February 17, 2026

Published for Opposition

August 19, 2025

Goods & Services

Medical and veterinary preparations for therapeutic purposes, namely, pharmaceutical preparations for treatment of genetic diseases; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceuticals for the delivery of genes to cells, all for medical purposes; chemical preparations for use in medical science, namely, in gene therapy and cell therapy; biologic preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposes, namely, adeno-associated viral preparations; pharmaceutical preparations in the nature of adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; pharmaceutical preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; adhesive pads for medical and surgical use

Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disorders, blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, renal and kidney disorders, hepatological disorders, or nervous system disorders; medical services, namely, gene and nucleic acid delivery and modification for therapeutic purposes in the fields of gene therapy and cell therapy; medical services, namely, gene therapy design and delivery in the fields of gene therapy and cell therapy; medical advisory services relating to gene therapy; provision of a website providing educational information relating to medical services, namely, gene therapy or genetic medicine; advisory, consultancy and information services relating to the treatment, relief and/or prevention of eye and ear disease, single gene disorders, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders; information, advice and consultancy services relating to the aforementioned services

Scientific and technological services and research or design relating thereto, namely, scientific research in the fields of gene therapy and cell therapy; industrial analysis and research services in the fields of gene therapy and cell therapy; biological and medical product research and development; preclinical and clinical research and development in the fields of gene therapy and cell therapy; gene therapy research; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials and consultancy relating thereto; biochemical assay development and performance, namely, monitoring of patients prior and subsequent to gene therapy; diagnostics development and performance, namely, monitoring of patients prior and subsequent to gene therapy; biomarker identification, namely, detection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation; scientific research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and ear, biotechnological preparations for the treatment of disorders relating to the eye and ear, preparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; information, advice and consultancy services relating to the aforementioned services

Custom manufacturing of pharmaceuticals and pharmaceutical processing; custom manufacturing of biotechnological pharmaceuticals and biopharmaceuticals and processing of biotechnological pharmaceuticals and biopharmaceuticals; biomanufacturing for others, namely, manufacturing of viral vectors using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals for gene therapy; pharmaceutical formulation being custom pharmaceutical manufacturing; information, advice and consultancy services relating to the aforementioned services

Medical and surgical apparatus and instruments for use in gene therapy and cell therapy; medical devices for use in gene therapy and cell therapy; apparatus and instruments for the administration of gene therapy products; ophthalmic surgery devices and instruments; veterinary apparatus and instruments for use in gene therapy and cell therapy; cannulae for use in ophthalmic procedures; needles for surgical and medical purposes; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic procedures, including surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; with none of the foregoing goods for the purpose of bowel management or collection of bodily waste

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 17, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 17, 2026 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 29, 2026 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 29, 2026 AITU
NOTICE OF ALLOWANCE CANCELLED
Oct 23, 2025 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Oct 23, 2025 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 11, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 6, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 6, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 21, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 21, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 21, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 18, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 18, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 18, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 18, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 19, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 19, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 19, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 2, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 25, 2024 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 11, 2024 PARI
NEW APPLICATION ENTERED
Jan 8, 2024 NWAP